PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportspseudomonas infections
MeSH D011552 - pseudomonas infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D016905:Gram-negative bacterial infections
$
Success rate
D011552: 
Pseudomonas infections
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCiprofloxacin Ciprofloxacin  2004-06-09   
Gentamicin Gentamicin  1991-11-21   
Tobramycin Tobramycin  1992-01-30   
Colistimethate Colobreathe  2012-02-13   
PadagisBacitracin, Polymyxin b Bacitracin Polymyxin B  2002-02-27   
Hydrocortisone, Bacitracin, Neomycin, Polymyxin b Bacitracin-neomycin-polymyxin W/ Hydrocortisone  1982-01-01   
Gentamicin Gentamicin  1982-01-01   
Bacitracin, Neomycin, Polymyxin b Neomycin Polymyxin B Sulfates Bacitracin  1982-01-01   
Dexamethasone, Neomycin, Polymyxin b Neomycin Polymyxin B Sulfates Dexamethasone  1989-07-31   
Dexamethasone, Tobramycin Tobramycin Dexamethasone  2022-02-11   
Taro PharmaceuticalCiprofloxacin Ciprofloxacin  2004-10-06   
Gentamicin Gentamicin  1983-05-26   
NATCO PharmaCiprofloxacin Ciprofloxacin  2004-06-09   
MylanTobramycin Tobramycin  2008-03-11   
ViatrisTobramycin Tobi  1997-12-22   
GSKPolymyxin b Aerosporin  1982-01-01   
Ceftazidime Ceptaz  1990-09-27   
Neomycin, Polymyxin b Neosporin  1985-01-14   
Ceftazidime Pentacef  1995-11-07   
Bacitracin, Polymyxin b Polysporin  1985-03-01   
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/6
Phase 2
0%
0/1
Phase 3
97%
31/32
Approved: 27Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Mylan
1
2
3
4
5
6
...
9
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use